Federal Register: April 4, 2001 (Volume 66, Number 65)
DOCID: FR Doc 01-8180
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
NOTICE: NOTICES
ACTION: Applications, hearings, determinations, etc.:
SUBJECT CATEGORY:
Manufacturer of Controlled Substances; Notice of Registration
DOCUMENT SUMMARY:
By Notice dated September 28, 2000, and published in the Federal Register on October 13, 2000, (65 FR 60978), Irix Pharmaceuticals, Inc., 101 Technology Place, Florence, South Carolina 29501, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of methylphenidate (1724), a basic class of controlled substance listed in Schedule II.
The firm plans to manufacture methylphenidate for demonstration purposes and for dosage form development and stability studies.
No comments or objections have been received. DEA has considered
the factors in Title 21, United States Code, Section 823(a) and
determined that the registration of Irix Pharmaceuticals, Inc. to
manufacture methylphenidate is consistent with the public interest at
this time. DEA has investigated the firm on a regular basis to ensure
that the company's continued registration is consistent with the public
interest. These investigations have included inspection and testing of
the company's physical security systems, audits of the company's
records, verification of the company's compliance with state and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy
Assistant Administrator, Office of Diversion Control, hereby orders
that the application submitted by the above firm for registration as a
bulk manufacturer of the basic class of controlled substance listed above is granted.
Dated: March 26, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 018180 Filed 4301; 8:45 am]
BILLING CODE 441009M
SUMMARY:
Irix Pharmaceuticals, Inc.,
DOCUMENT BODY 2:
By Notice dated September 28, 2000, and published in the Federal Register on October 13, 2000, (65 FR 60978), Irix Pharmaceuticals, Inc., 101 Technology Place, Florence, South Carolina 29501, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of methylphenidate (1724), a basic class of controlled substance listed in Schedule II.
The firm plans to manufacture methylphenidate for demonstration purposes and for dosage form development and stability studies.
No comments or objections have been received. DEA has considered
the factors in Title 21, United States Code, Section 823(a) and
determined that the registration of Irix Pharmaceuticals, Inc. to
manufacture methylphenidate is consistent with the public interest at
this time. DEA has investigated the firm on a regular basis to ensure
that the company's continued registration is consistent with the public
interest. These investigations have included inspection and testing of
the company's physical security systems, audits of the company's
records, verification of the company's compliance with state and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy
Assistant Administrator, Office of Diversion Control, hereby orders
that the application submitted by the above firm for registration as a
bulk manufacturer of the basic class of controlled substance listed above is granted.
Dated: March 26, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 018180 Filed 4301; 8:45 am]
BILLING CODE 441009M